- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Loading...
Express Scripts will put “multiple” biosimilar versions of Humira, the expensive rheumatoid arthritis drug from AbbVie, in the “same position” as the brand-name medicine on its formulary in
2023, Forbes notes. Humira, approved by the FDA 20 years ago, has been one of the nation’s costliest drugs, generating more than $20 billion in sales in 2021 alone. Express Scripts said
Humira, which treats inflammatory and skin conditions, is one of the most widely used specialty medications, which account for just 2% of prescriptions but drive half of drug spending.
OptumRx, another large pharmacy benefit manager, also plans to take the same step.
